Windlas Biotech Share Price Target 2025, 2026, 2028, 2030, 2040 and 2050

In this article, we will discuss Windlas Biotech Share Price Target 2025, 2026, 2028, 2030, 2040 and 2050 on the basis of growth pattern, technical indicators, market sentiment of last several years. Fundamental and technical analysis will also be analyzed for better understanding of the price prediction of the company. It is very important for a long term investor to have knowledge of all these parameters so that they can set their targets in the future and earn good profits.

What is Windlas Biotech

Windlas Biotech, a company in the Pharmaceuticlas sector, is a famous pharmaceutical company in India, it is known for manufacturing both solid and liquid medicines. The Chairman and Industrial Director of the company is Vivek Dhariwal, it was established on 19 February 2001.

Windlas Biotech discovers and develops new medicines and also produces complex generic products. It serves the semi-urban and rural communities of India with the medicines and Ayurvedic products manufactured by it. Its expansion is spread in more than 14 states of India. Windlas Biotech’s major therapeutic segments are cardiovascular, anti-diabetic, neurological, psychiatric, and respiratory.

Windlas Biotech Fundamental

Windlas Biotech, valued at ₹1,490Cr, has a strong hold in the Indian market, due to which its popularity is increasing among investors. In this financial year, it has given a very good return of 12.91% on the investment of its shareholders and the ROCE of the company is also 17.17%, which shows that the company is using its capital quite efficiently.

Windlas Biotech’s P/E Ratio (TTM) is 25.63 and P/B Ratio is 3.31. Investors are able to earn money but the return percentage is low. The EPS and Book Value Per Share of the company are ₹27.96 and ₹216.51 respectively, which indicates its strong position.

Compared to the financial year 2023, the company has generated 22.80% and 38.09% more sales and profit this year. Its continuously increasing sales and profits for the last 5 years reflect its strong position.

Windlas Biotech Listing date

Windlas Biotech is listed on both NSE and BSE. It was listed on the stock exchange on August 2, 2021 at Rs 435.

Windlas Biotech Share Price History

When Windlas Biotech company was listed in the stock market, the share price of the company was Rs 435 and today on 19 July 2024, the share price of the company has increased to Rs 694. The company’s shares have increased by 110.40% in the last one year. The current market capital of the company is ₹1,490Cr, which comes under small cap.

The company has given a profit of 31.14% in the last 3 months. Its shares have seen a negative growth of 2.99% and 1.97% in the last one month and one week respectively.

Even though its share price has fallen in the last one month, this stock looks quite good from the point of view of long term investment.

Windlas Biotech Share Price growth chart

The growth chart of Windlas Biotech shows that the company’s share price fell only in 2022, but since then the company has been continuously giving profits. So far in 2024, a growth of 43.68% has been seen in the company’s share.

Windlas Biotech Profit/Loss – Last 4 Years Report

Income Report

Expenses

Profit/Loss

Windlas Biotech company has been giving continuous profits for the last 3 years. The total revenue of the company in the financial year 2022 was Rs 472.64 crore on which the company made a profit of Rs 38.09 crore. The total revenue of the company in the financial year 2024 was Rs 644.42 crore and on this revenue the company has earned a profit of Rs 58.19 crore, which is the highest profit in the last 3 years.

Tax Expenses

Profit/Loss After Tax

Other Additional Information

Dividend

Windlas Biotech Balance Sheet – Last 4 Years Report:

Equities and Liabilities

Assets

Other Additional Information

Windlas Biotech Quarterly Result

Windlas Biotech Share Price Target 2024, 2025, 2026, 2028, 2030, 2040 and 2050

Windlas Biotech Share Price Target 2024

Windlas Biotech Share Price Target 2025

Windlas Biotech Share Price Target 2026

Windlas Biotech Share Price Target 2028

Windlas Biotech Share Prediction: Expert Opinion

Windlas Biotech Share Price Target 2030

Windlas Biotech Share Price Target 2040

Windlas Biotech Share Price Target 2050

How to Buy Windlas Biotech Share?

There are many brokers available to buy and sell shares of any company in the Indian market. You can buy and sell shares of the company only when you have a demat account. Here a list of many brokers is being given in which you can open your demat account.

• Zerodha
• Groww
• Angel One
• Upstox

Shareholding Pattern

Latest News

• Windlas Biotech promoters have reduced their stake from 62.82% to 62.51% and Mutual Funds have reduced their stake from 10.37% to 8.70%.
• FII/FPI has increased its holding from 1.18% to 1.59% in June 2024.
• The company had net sales of Rs 140.71 crore in March 2023. The company has made total net sales of Rs 171.29 crore this year in March 2024, an increase of 21.73% compared to last year.
• The company’s net profit in the quarter of March 2024 was Rs 16.95 crore, which is 48.05% more than the same quarter last year.
• The company’s EBITDA increased by 40.47% in March 2024 compared to March 2023. The company’s EBITDA in March 2024 stood at Rs 26.38 crore.
• The company has given a return of 162.44% in the last one year.

Strengths

• High TTM EPS Growth: Windlas Biotech’s TTM EPS has registered a significant growth of ₹ 27.96 for the last 12 months, which reflects the efficient management strategy of the company due to which investors are earning good profits on their shares.
• ROE and ROCE improving in last 2 years: For the last 2-3 years, the company has been continuously generating income by using its shareholder’s funds very well and at the same time it has also used its revenue very well, due to which Its ROCE has also increased continuously. ROE and ROCE in FY 23 and 24 are 10.59%, 12.91% and 14.17%, 17.17% respectively.
• Growth in Net Profit: Windlas Biotech has continuously given good profits to investors for the last 4 years. In the financial years 21, 22, 23 and 24, the company has given profits of 5.01Cr, 38.56Cr, 42.64Cr and 58.14Cr, and its profit margin has also increased quarter on quarter. The company’s continued revenue growth reflects its strong potential in the competitive market.
• ‘0’ Debt: Windlas Biotech currently has no debt, which means that if any financial risk comes to it in the future, the company can face it with strength. 0 debt/equity is a good ratio for investors.
• Book Value per share Improving: The book value per share of the company has improved significantly in the last 2 years. Its book value per share in financial years 2023 and 24 was 192.42 and 216.51 respectively. The improvement in book value reflects the increase in its intrinsic value and strong financial position.
• FII / FPI or Institutions increasing their shareholding: Foreign institutional investors (FII), foreign portfolio investors (FPI) and other companies are increasing the shareholding of Windlas Biotech. The growing interest in Windlas Biotech from foreign institutional investors highlights the company’s strong fundamentals and future growth prospects.

Risks

• High P/E And P/B Ratio: The P/E Ratio (TTM) of the company is 25.63 and P/B Ratio is 3.31 which is quite high from the point of view of long term investment.
• Declining Net Cash Flow: The company has seen a loss in net cash, the company is unable to get net cash.

Windlas Biotech Points to Consider Before Investing

1. Windlas Biotech is 9.70% away from its 52 week high zone and 134.29% away from its 52 week low zone.

2. In last 1 month, Nifty 50 has gained 4.89% while Windlas Biotech has recorded a decline of -0.96% which indicates its underperformance.

3. Windlas Biotech’s Market Cap is above the industry level and TTM PE ratio is below the industry level and Net Profit % and Revenue Growth are also below the industry average. It is very important to keep these points in mind from investment point of view.

Competitors of Windlas Biotech

1. Concord Biotech
2. Biocon
3. Sun Pharma Adv
4. Piramal Phytoca
5. DIVISLAB
6. CIPLA
7. ZYDUSLIFE

Similar Stocks

Profitable Stocks

Conclusion

The company has been continuously giving profits and in the last 2 years the company has made a lot of improvement in its ROCE and ROE and the dept on the company is also negligible. After analyzing all these aspects, it can be expected that the company will The share price may increase in future. The company can give very good profits to its investors.

Disclaimer– Please note that all the information given here is for general information purpose only and not for investment purposes. Therefore, before investing in any share, take advice from a certified market expert. If you invest, you will be responsible for your profits and losses.

Also Read:

Then don’t say that I didn’t tell you, buy Waaree Energies shares right now.

Tata Gold Price Target, money printing machine for small investors.

Adani Power price target, share will increase 10 times.

Tata Steel price target, trust of more than 100 years old company.

SW Solar price target, guarantee boom in solar sector.

Tata Power share price target, guaranteed returns.

Yatra Online shares will make you rich, 100% guarantee.

Den Networks Share Price Target 2024, to 2050

Venus Pipes Share Price Target 2023 to 2050